Born in 1958, Marc de Garidel is a graduate of École Spéciale des Travaux Publics (a leading French civil engineering school), and holds a Master’s degree from the Thunderbird School of Global Management (Arizona, US) and an Executive MBA from Harvard Business School (Massachusetts, US). He began his career with pharmaceutical company Eli Lilly in 1983, where he held various roles, mainly finance-related, in France, the US and Germany. In 1995, Marc de Garidel joined Amgen, an American biotech company, where he held positions of increasing responsibility in finance. In 1998, he was appointed Corporate Controller of Amgen, based in the US. In 2000, he takes up operational responsibilities in France, and progressively oversaw an increasing number of countries before heading the Southern region of Amgen International, the group’s most important region in terms of sales. Between 2010 and 2012, Marc de Garidel was Chairman of the European Biopharmaceutical Enterprises association. Marc de Garidel has been Chairman and spokesperson of the G5, an association of eight leading French healthcare companies, since January 2011. He has been Vice-President of France’s Healthcare Industries and Technologies Strategic Committee since July 2011. Marc de Garidel is Vice-President and a board member of the EFPIA (European Federation of Pharmaceutical Industries and Associations). He is a member of the Innovative Medecines Initiative (IMI) Governing Board. Marc de Garidel is a knight of France’s National Order of the Legion of Honor and a board member of the Society of Members of the Legion of Honor. He teaches at the Master’s Programs of French business schools, ESSEC and ESCP Europe. Born in 1958, Marc de Garidel is a graduate of École Spéciale des Travaux Publics (a leading French civil engineering school), and holds a Master’s degree from the Thunderbird School of Global Management (Arizona, US) and an Executive MBA from Harvard Business School (Massachusetts, US). He began his career with pharmaceutical company Eli Lilly in 1983, where he held various roles, mainly finance-related, in France, the US and Germany. In 1995, Marc de Garidel joined Amgen, an American biotech company, where he held positions of increasing responsibility in finance. In 1998, he was appointed Corporate Controller of Amgen, based in the US. In 2000, he takes up operational responsibilities in France, and progressively oversaw an increasing number of countries before heading the Southern region of Amgen International, the group’s most important region in terms of sales. Between 2010 and 2012, Marc de Garidel was Chairman of the European Biopharmaceutical Enterprises association. Marc de Garidel has been Chairman and spokesperson of the G5, an association of eight leading French healthcare companies, since January 2011. He has been Vice-President of France’s Healthcare Industries and Technologies Strategic Committee since July 2011. Marc de Garidel is Vice-President and a board member of the EFPIA (European Federation of Pharmaceutical Industries and Associations). He is a member of the Innovative Medecines Initiative (IMI) Governing Board. Marc de Garidel is a knight of France’s National Order of the Legion of Honor and a board member of the Society of Members of the Legion of Honor. He teaches at the Master’s Programs of French business schools, ESSEC and ESCP Europe.

Regulatory Affairs